A Study to Evaluate FK778 in Kidney Transplant Patients
A Multicentre, Randomised, Double-Blind, Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Different Concentrations of FK778 With Tacrolimus (FK506) and Steroids Versus a Standard Regimen of Tacrolimus, MMF and Steroids in Renal Transplant Patients
Sponsor: Astellas Pharma Europe B.V.
This PHASE2 trial investigates Grafting, Kidney and Kidney Transplantation and is currently completed. Astellas Pharma Europe B.V. leads this study, which shows 6 recorded versions since 2003 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Sep 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Astellas Pharma Europe B.V.
- Astellas Pharma Inc
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Barcelona, Spain , Berlin, Germany , Brest, France , Brussels, Belgium , Bydgoszcz, Poland , Créteil, France , Córdoba, Spain , Essen, Germany , Frankfurt, Germany , Grenoble, France and 22 more locations